25 July 2017 - Deborah Wilkes
Archived
Sales at RB's Health division were down by 4% on a like-for-like basis in the second quarter of 2017. The company said declines for Scholl/Amopé footcare products had continued to have an impact, and "cyberattack issues" at the very end of the quarter had contributed to the fall.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.